Tyra Bioscience, Inc TYRA

Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeutics, Tyra Biosciences, and Oscar Health.

Tyra Biosciences, Inc. (NASDAQ:TYRA) reported initial Phase 2 SURF302 results on September 9 for dabogratinib, an investigational oral FGFR3 inhibitor. The study enrolled patients with FGFR3-altered low-grade, intermediate-risk non-muscle-invasive bladder cancer. At the August 31, 2026 cutoff, 14 participants receiving 60 mg once daily had received treatment and completed at least the three-month disease assessment, […]

Tyra Biosciences has seen its share price swing sharply around recent trial updates and capital plans, which puts a fresh spotlight on what investors are really paying for against its book value. With the stock resetting after mixed bladder cancer drug data and a sizeable equity offering, the question is how closely that current market price lines up with the assets on its balance sheet. Over the past year, Tyra Biosciences has gained about 105.7%, which raises the issue of whether that move...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the pricing of an underwritten offering of 9,079,000 shares of its common stock at a price of $22.03 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 9,078,529 shares of common stock at a purchase price of $22

Tyra stock plummeted to a 10-month low Wednesday on mixed test results for its experimental bladder cancer treatment.

Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.

Tyra Biosciences and Johnson & Johnson are pursuing their own approaches to treating a common, early-stage form of bladder cancer.

Tyra Biosciences (NASDAQ:TYRA) shares dropped 30% on Wednesday after the biotechnology company released initial results from its Phase 2 SURF302 trial of dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer. At the 60 mg once-daily dose, dabogratinib produced a 79% overall response rate and a 64% complete response rate as the best overall response among patients with single and multiple marker lesions combined.

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). The study provided clinical proof of concept for selective oral FGFR3 inhibit

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conference:

Tyra is set to host a conference call on September 9 to discuss initial results from its Phase 2 study evaluating Dabogratinib in patients with intermediate-risk non-muscle invasive bladder cancer.

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on Wednesday, September 9, 2026 at 8:00 am ET to discuss initial clinical results from the SURF302 Phase 2 study evaluating oral dabogratinib for intermediate risk non-muscle invasive bladder cancer (IR NMIBC).

Dr. Charlton brings over 15 years of rare disease and pediatric drug development experience including CMO and clinical development roles Appointment further strengthens clinical leadership and execution capabilities ahead of planned SOTERIA Phase 2 initiation in Q4 2026 PARAMUS, NJ, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare pediatric lysosomal storage disorders (“LSDs

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate progress.

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Tyra Biosciences, Inc. (NASDAQ:TYRA) is one of the most promising stocks on our list. TheFly reported on June 17 that Oppenheimer initiated coverage of TYRA with an Outperform rating and a $50 price target. The firm highlighted TYRA’s upcoming clinical […]